$1.09
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Cardiff Oncology to Participate in September 2026 Conferences
CRDF: Second Quarter Earnings
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform
Overview
52-week range
$0.76
$3.31
13% of range
Avg surprise (last 3)
-18.1%
Avg reaction (last 2)
+4.0%
100% positive
Latest IV / EM
147%
EM ±22.9% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.14 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-0.18 | $-0.13 | -38.5% | +10.0% | +2.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.17 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $-0.21 | $-0.19 | -10.5% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.20 | $-0.19 | -5.3% | — | +5.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.22 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.25 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.25 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $104,000 | $41,000 | — | $120,000 | $121,000 | $109,000 | — | $165,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-10M | $-13M | — | $-12M | $-15M | $-14M | — | $-13M |
| Net income | $-9M | $-12M | — | $-11M | $-14M | $-13M | — | $-12M |
| EPS (diluted) | $-0.14 | $-0.18 | — | $-0.17 | $-0.21 | $-0.20 | — | $-0.25 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9M | $9M | $17M | $10M | $11M | $24M | $51M | $13M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $36M | $47M | $60M | $62M | $74M | $83M | $95M | $59M |
| Total assets | $37M | $49M | $62M | $64M | $76M | $85M | $97M | $63M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $14M | $16M | $15M | $17M | $14M | $14M | $14M |
| Total equity | $27M | $35M | $45M | $49M | $59M | $71M | $83M | $49M |